504432289 06/27/2017

# PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT4478990

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

#### **CONVEYING PARTY DATA**

Name	Execution Date
SOLVIAS AG	12/04/2014

## **RECEIVING PARTY DATA**

Name:	JANSSEN PHARMACEUTICA NV	
Street Address:	TURNHOUTSEWEG 30	
City:	BEERSE	
State/Country:	BELGIUM	
Postal Code:	B-2340	

### **PROPERTY NUMBERS Total: 1**

Property Type	Number
Application Number:	15531780

### **CORRESPONDENCE DATA**

**Fax Number:** (937)449-6405

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

**Phone:** 937-449-6400

Email: diane.polzella@dinsmore.com

Correspondent Name: DINSMORE & SHOHL, LLP FIFTH THIRD CENTER

Address Line 1: ONE SOUTH MAIN STREET

Address Line 2: SUITE 1300

Address Line 4: DAYTON, OHIO 45402

ATTORNEY DOCKET NUMBER:	JPN 0001 PA/OCM-004	
NAME OF SUBMITTER:	DIANE POLZELLA	
SIGNATURE:	/Diane Polzella/	
DATE SIGNED:	06/27/2017	

**Total Attachments: 1** 

source=Signed\_Assign\_SolviasAG\_to\_Janssen#page1.tif

PATENT 504432289 REEL: 042823 FRAME: 0016

### **General Assignment**

WHEREAS, **Solvias AG**, having its place of business at Römerpark 2, CH-4303 Kaiseraugst, Switzerland (hereinafter referred to as "Assignor"), is the owner of certain new and useful inventions relating to

#### 'A TRIAZOLOPYRIDAZINE AS A KINASE MODULATOR'

for which on the 4<sup>th</sup> day of December 2014, European Patent Application no. 14196387.6 was filed at the European Patent Office and on the 5<sup>th</sup> day of December 2014, European Patent Application no. 14196585.5 was filed at the European Patent Office.

WHEREAS, Janssen Pharmaceutica NV, having its place of business at Turnhoutseweg 30, B-2340 Beerse, Belgium (hereinafter referred to as "Assignee") is desirous of acquiring Assignor's entire right, title and interest therein, including the right to claim priority thereof,

NOW, THEREFORE, BE IT KNOWN, that in view of good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Assignor hereby assigns and transfers, for all countries in the world, to said Assignee its entire right, title and interest, including the right to claim priority, in and to all said inventions disclosed in said applications and in and to said applications, and all foreign equivalents thereof, including all substitutions, divisions, and continuations thereof, and in and to all Letters Patent, that may be granted for said inventions, and in and to all extensions, renewals, and reissues thereof, the same to be held and enjoyed by said Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment had not been made.

And for purpose of obtaining patent protection in any foreign country, the Assignor hereby agrees that, any right, title and interest, in and to all said inventions disclosed in said applications and in and to said applications, and all foreign equivalents thereof can be directly assigned by the inventors to the Assignee without explicit confirmation of the Assignor.

The Assignor agrees that this general assignment is effective from the 4th day of December 2014.

IN TESTIMONY WHEREOF, the Assignor and Assignee set hereunto their hand and seal this date.

For Solvias AG

Fritz Thommen

SVP, Contracts Management

Authorized Signatory

Urs Siegrist

EVP, Head of Speciality Chemicals and Ligands

Authorized Signatory

For Janssen Pharmaceutica NV

Frank Daelemans

Janssen Pharmaceutica NV

Authorized Signatory

PATENT REEL: 042823 FRAME: 0017

RECORDED: 06/27/2017